Intrinsic value of Summit Therapeutics ADR - SMMT

Previous Close

$1.39

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$1.39

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of SMMT stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  56
  86
  129
  187
  264
  362
  486
  639
  822
  1,038
  1,289
  1,576
  1,899
  2,259
  2,657
  3,090
  3,560
  4,064
  4,603
  5,175
  5,780
  6,417
  7,085
  7,785
  8,516
  9,278
  10,071
  10,897
  11,756
  12,648
Variable operating expenses, $m
  131
  201
  299
  433
  609
  837
  1,122
  1,473
  1,895
  2,392
  2,968
  3,629
  4,374
  5,204
  6,119
  7,117
  8,199
  9,361
  10,601
  11,919
  13,312
  14,779
  16,318
  17,930
  19,613
  21,368
  23,196
  25,097
  27,074
  29,129
Fixed operating expenses, $m
  30
  30
  31
  32
  32
  33
  34
  35
  35
  36
  37
  38
  38
  39
  40
  41
  42
  43
  44
  45
  46
  47
  48
  49
  50
  51
  52
  53
  55
  56
Total operating expenses, $m
  161
  231
  330
  465
  641
  870
  1,156
  1,508
  1,930
  2,428
  3,005
  3,667
  4,412
  5,243
  6,159
  7,158
  8,241
  9,404
  10,645
  11,964
  13,358
  14,826
  16,366
  17,979
  19,663
  21,419
  23,248
  25,150
  27,129
  29,185
Operating income, $m
  -105
  -145
  -201
  -277
  -378
  -507
  -670
  -869
  -1,108
  -1,391
  -1,716
  -2,091
  -2,513
  -2,984
  -3,502
  -4,068
  -4,681
  -5,339
  -6,042
  -6,789
  -7,578
  -8,409
  -9,281
  -10,193
  -11,147
  -12,141
  -13,176
  -14,253
  -15,373
  -16,537
EBITDA, $m
  -102
  -142
  -198
  -274
  -374
  -502
  -664
  -862
  -1,100
  -1,381
  -1,706
  -2,079
  -2,499
  -2,967
  -3,482
  -4,045
  -4,654
  -5,309
  -6,008
  -6,750
  -7,534
  -8,361
  -9,228
  -10,135
  -11,083
  -12,071
  -13,101
  -14,172
  -15,285
  -16,442
Interest expense (income), $m
  0
  1
  11
  25
  44
  71
  107
  152
  210
  280
  365
  465
  581
  713
  863
  1,030
  1,213
  1,414
  1,631
  1,864
  2,113
  2,378
  2,657
  2,952
  3,261
  3,584
  3,922
  4,275
  4,642
  5,023
  5,420
Earnings before tax, $m
  -106
  -156
  -226
  -322
  -449
  -614
  -822
  -1,079
  -1,388
  -1,756
  -2,181
  -2,671
  -3,226
  -3,847
  -4,532
  -5,281
  -6,095
  -6,970
  -7,906
  -8,902
  -9,956
  -11,066
  -12,233
  -13,454
  -14,731
  -16,063
  -17,451
  -18,895
  -20,397
  -21,957
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -106
  -156
  -226
  -322
  -449
  -614
  -822
  -1,079
  -1,388
  -1,756
  -2,181
  -2,671
  -3,226
  -3,847
  -4,532
  -5,281
  -6,095
  -6,970
  -7,906
  -8,902
  -9,956
  -11,066
  -12,233
  -13,454
  -14,731
  -16,063
  -17,451
  -18,895
  -20,397
  -21,957

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  115
  178
  266
  386
  544
  748
  1,005
  1,319
  1,698
  2,144
  2,663
  3,255
  3,924
  4,668
  5,489
  6,385
  7,355
  8,398
  9,511
  10,693
  11,942
  13,258
  14,639
  16,085
  17,595
  19,169
  20,809
  22,515
  24,289
  26,132
Adjusted assets (=assets-cash), $m
  115
  178
  266
  386
  544
  748
  1,005
  1,319
  1,698
  2,144
  2,663
  3,255
  3,924
  4,668
  5,489
  6,385
  7,355
  8,398
  9,511
  10,693
  11,942
  13,258
  14,639
  16,085
  17,595
  19,169
  20,809
  22,515
  24,289
  26,132
Revenue / Adjusted assets
  0.487
  0.483
  0.485
  0.484
  0.485
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
  0.484
Average production assets, $m
  13
  19
  29
  42
  59
  82
  109
  144
  185
  233
  290
  354
  427
  508
  598
  695
  801
  914
  1,036
  1,164
  1,301
  1,444
  1,594
  1,752
  1,916
  2,088
  2,266
  2,452
  2,645
  2,846
Working capital, $m
  -7
  -11
  -16
  -23
  -33
  -45
  -60
  -79
  -102
  -129
  -160
  -195
  -235
  -280
  -329
  -383
  -441
  -504
  -571
  -642
  -717
  -796
  -879
  -965
  -1,056
  -1,150
  -1,249
  -1,351
  -1,458
  -1,568
Total debt, $m
  40
  92
  166
  266
  398
  569
  783
  1,045
  1,361
  1,734
  2,167
  2,662
  3,220
  3,842
  4,527
  5,275
  6,085
  6,956
  7,885
  8,872
  9,916
  11,014
  12,168
  13,375
  14,635
  15,950
  17,319
  18,744
  20,225
  21,764
Total liabilities, $m
  96
  148
  222
  322
  455
  625
  839
  1,102
  1,417
  1,790
  2,223
  2,718
  3,276
  3,898
  4,583
  5,332
  6,142
  7,012
  7,941
  8,928
  9,972
  11,071
  12,224
  13,431
  14,692
  16,006
  17,375
  18,800
  20,281
  21,820
Total equity, $m
  19
  29
  44
  64
  90
  124
  166
  218
  280
  354
  439
  537
  647
  770
  906
  1,054
  1,214
  1,386
  1,569
  1,764
  1,971
  2,188
  2,415
  2,654
  2,903
  3,163
  3,433
  3,715
  4,008
  4,312
Total liabilities and equity, $m
  115
  177
  266
  386
  545
  749
  1,005
  1,320
  1,697
  2,144
  2,662
  3,255
  3,923
  4,668
  5,489
  6,386
  7,356
  8,398
  9,510
  10,692
  11,943
  13,259
  14,639
  16,085
  17,595
  19,169
  20,808
  22,515
  24,289
  26,132
Debt-to-equity ratio
  2.100
  3.150
  3.780
  4.180
  4.440
  4.610
  4.720
  4.800
  4.860
  4.900
  4.930
  4.960
  4.970
  4.990
  5.000
  5.010
  5.010
  5.020
  5.020
  5.030
  5.030
  5.030
  5.040
  5.040
  5.040
  5.040
  5.040
  5.050
  5.050
  5.050
Adjusted equity ratio
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165
  0.165

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -106
  -156
  -226
  -322
  -449
  -614
  -822
  -1,079
  -1,388
  -1,756
  -2,181
  -2,671
  -3,226
  -3,847
  -4,532
  -5,281
  -6,095
  -6,970
  -7,906
  -8,902
  -9,956
  -11,066
  -12,233
  -13,454
  -14,731
  -16,063
  -17,451
  -18,895
  -20,397
  -21,957
Depreciation, amort., depletion, $m
  3
  3
  3
  4
  4
  5
  6
  7
  9
  10
  10
  12
  14
  17
  20
  23
  27
  30
  35
  39
  43
  48
  53
  58
  64
  70
  76
  82
  88
  95
Funds from operations, $m
  -103
  -153
  -222
  -318
  -445
  -609
  -816
  -1,072
  -1,380
  -1,745
  -2,171
  -2,660
  -3,212
  -3,830
  -4,512
  -5,258
  -6,068
  -6,940
  -7,872
  -8,863
  -9,912
  -11,018
  -12,179
  -13,396
  -14,667
  -15,994
  -17,375
  -18,813
  -20,308
  -21,863
Change in working capital, $m
  -3
  -4
  -5
  -7
  -10
  -12
  -15
  -19
  -23
  -27
  -31
  -36
  -40
  -45
  -49
  -54
  -58
  -63
  -67
  -71
  -75
  -79
  -83
  -87
  -91
  -94
  -98
  -102
  -106
  -111
Cash from operations, $m
  -100
  -149
  -217
  -311
  -436
  -597
  -801
  -1,053
  -1,357
  -1,719
  -2,140
  -2,624
  -3,172
  -3,785
  -4,463
  -5,204
  -6,010
  -6,877
  -7,805
  -8,792
  -9,837
  -10,939
  -12,097
  -13,309
  -14,577
  -15,899
  -17,277
  -18,711
  -20,202
  -21,752
Maintenance CAPEX, $m
  0
  0
  -1
  -1
  -1
  -2
  -3
  -4
  -5
  -6
  -8
  -10
  -12
  -14
  -17
  -20
  -23
  -27
  -30
  -35
  -39
  -43
  -48
  -53
  -58
  -64
  -70
  -76
  -82
  -88
New CAPEX, $m
  -5
  -7
  -10
  -13
  -17
  -22
  -28
  -34
  -41
  -49
  -56
  -65
  -73
  -81
  -89
  -98
  -106
  -114
  -121
  -129
  -136
  -143
  -150
  -157
  -164
  -171
  -179
  -186
  -193
  -201
Cash from investing activities, $m
  -5
  -7
  -11
  -14
  -18
  -24
  -31
  -38
  -46
  -55
  -64
  -75
  -85
  -95
  -106
  -118
  -129
  -141
  -151
  -164
  -175
  -186
  -198
  -210
  -222
  -235
  -249
  -262
  -275
  -289
Free cash flow, $m
  -105
  -156
  -227
  -325
  -454
  -621
  -831
  -1,091
  -1,403
  -1,773
  -2,204
  -2,698
  -3,257
  -3,880
  -4,569
  -5,322
  -6,139
  -7,017
  -7,957
  -8,955
  -10,012
  -11,126
  -12,295
  -13,520
  -14,800
  -16,135
  -17,525
  -18,972
  -20,477
  -22,041
Issuance/(repayment) of debt, $m
  36
  52
  74
  100
  132
  170
  214
  263
  316
  373
  433
  495
  558
  622
  685
  748
  810
  870
  929
  987
  1,043
  1,099
  1,153
  1,207
  1,261
  1,315
  1,369
  1,424
  1,481
  1,539
Issuance/(repurchase) of shares, $m
  113
  166
  240
  342
  476
  648
  865
  1,131
  1,451
  1,829
  2,266
  2,769
  3,337
  3,969
  4,667
  5,429
  6,255
  7,142
  8,090
  9,097
  10,162
  11,283
  12,460
  13,693
  14,980
  16,323
  17,721
  19,176
  20,689
  22,262
Cash from financing (excl. dividends), $m  
  149
  218
  314
  442
  608
  818
  1,079
  1,394
  1,767
  2,202
  2,699
  3,264
  3,895
  4,591
  5,352
  6,177
  7,065
  8,012
  9,019
  10,084
  11,205
  12,382
  13,613
  14,900
  16,241
  17,638
  19,090
  20,600
  22,170
  23,801
Total cash flow (excl. dividends), $m
  43
  62
  86
  117
  154
  197
  247
  303
  364
  429
  495
  566
  638
  711
  784
  855
  926
  995
  1,063
  1,129
  1,193
  1,256
  1,319
  1,380
  1,442
  1,503
  1,565
  1,629
  1,694
  1,760
Retained Cash Flow (-), $m
  -113
  -166
  -240
  -342
  -476
  -648
  -865
  -1,131
  -1,451
  -1,829
  -2,266
  -2,769
  -3,337
  -3,969
  -4,667
  -5,429
  -6,255
  -7,142
  -8,090
  -9,097
  -10,162
  -11,283
  -12,460
  -13,693
  -14,980
  -16,323
  -17,721
  -19,176
  -20,689
  -22,262
Prev. year cash balance distribution, $m
  2
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  -68
  -104
  -154
  -225
  -322
  -451
  -618
  -828
  -1,087
  -1,400
  -1,771
  -2,203
  -2,699
  -3,258
  -3,884
  -4,574
  -5,329
  -6,147
  -7,027
  -7,968
  -8,969
  -10,027
  -11,142
  -12,313
  -13,539
  -14,820
  -16,156
  -17,548
  -18,996
  -20,501
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  -65
  -95
  -134
  -185
  -249
  -327
  -417
  -517
  -625
  -734
  -841
  -940
  -1,026
  -1,094
  -1,140
  -1,162
  -1,159
  -1,132
  -1,082
  -1,013
  -928
  -832
  -730
  -627
  -527
  -432
  -347
  -271
  -207
  -154
Current shareholders' claim on cash, %
  13.3
  1.9
  0.3
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI). Its lead DMD product candidate is ezutromid, which is an orally administered small molecule. Its lead CDI product candidate is ridinilazole, which is an orally administered small molecule antibiotic. Its Ridinilazole is in Phase II clinical trials. It has conducted over three Phase I clinical trials of ezutromid. Its DMD program is based on utrophin modulation. It has received an orphan drug designation to ezutromid for the treatment of DMD. It is also developing an earlier-stage pipeline of second and future generation utrophin modulators for the treatment of DMD.

FINANCIAL RATIOS  of  Summit Therapeutics ADR (SMMT)

Valuation Ratios
P/E Ratio 0
Price to Sales 0
Price to Book 0
Price to Tangible Book
Price to Cash Flow 0
Price to Free Cash Flow 0
Growth Rates
Sales Growth Rate -100%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate NaN%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio NaN
Current Ratio NaN
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 0%
Ret/ On Assets - 3 Yr. Avg. 0%
Return On Total Capital 0%
Ret/ On T. Cap. - 3 Yr. Avg. 0%
Return On Equity 0%
Return On Equity - 3 Yr. Avg. 0%
Asset Turnover 0
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 0%
EBITDA Margin - 3 Yr. Avg. 0%
Operating Margin 0%
Oper. Margin - 3 Yr. Avg. 0%
Pre-Tax Margin 0%
Pre-Tax Margin - 3 Yr. Avg. 0%
Net Profit Margin 0%
Net Profit Margin - 3 Yr. Avg. 0%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

SMMT stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the SMMT stock intrinsic value calculation we used $34.8205479452 million for the last fiscal year's total revenue generated by Summit Therapeutics ADR. The default revenue input number comes from 0001 income statement of Summit Therapeutics ADR. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our SMMT stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for SMMT is calculated based on our internal credit rating of Summit Therapeutics ADR, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Summit Therapeutics ADR.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of SMMT stock the variable cost ratio is equal to 237.1%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $29 million in the base year in the intrinsic value calculation for SMMT stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 26.8% for Summit Therapeutics ADR.

Corporate tax rate of 27% is the nominal tax rate for Summit Therapeutics ADR. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the SMMT stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for SMMT are equal to 22.5%.

Life of production assets of 44.9 years is the average useful life of capital assets used in Summit Therapeutics ADR operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for SMMT is equal to -12.4%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $13.5273972603 million for Summit Therapeutics ADR - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 14.063 million for Summit Therapeutics ADR is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Summit Therapeutics ADR at the current share price and the inputted number of shares is $0.0 billion.

RELATED COMPANIES Price Int.Val. Rating
SRPT Sarepta Therap 111.99 2.96  str.sell
FGEN FibroGen 39.49 2.04  str.sell
PTCT PTC Therapeuti 31.71 214.00  str.buy
PRTK Paratek Pharma 7.18 0.65  str.sell
MRK Merck&Co 74.09 33.05  str.sell

COMPANY NEWS

▶ Appointment of Joint Broker   [02:00AM  GlobeNewswire]
▶ Holding(s) in Company   [Nov-01-18 12:34PM  GlobeNewswire]
▶ Director/PDMR Shareholding   [Oct-24-18 11:15AM  GlobeNewswire]
▶ Award of Share Options   [Oct-22-18 02:00AM  GlobeNewswire]
▶ Surrender of Share Options   [Oct-08-18 02:00AM  GlobeNewswire]
▶ Total voting rights   [Sep-03-18 09:12AM  GlobeNewswire]
▶ Summit Therapeutics Joins Antimicrobials Working Group   [Jul-30-18 10:47AM  PR Newswire]
▶ Cambridge biotech Summit pivots from failed trial, layoffs with $4.5M from CARB-X   [Jul-10-18 09:19PM  American City Business Journals]
▶ Summit Announces PhaseOut DMD Did Not Meet Primary Endpoint   [Jun-27-18 07:00AM  GlobeNewswire]
▶ Summit Therapeutics to Present at the Biotech Showcase   [Jan-09-18 07:00AM  GlobeNewswire]
▶ Summit Therapeutics to Host R&D Day 11 October 2017   [Oct-02-17 07:00AM  GlobeNewswire]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.